Genentech announces Bill Anderson as new CEO
Genentech, the biotech subsidiary of Roche, has announced that Genentech veteran, Ian Clark, will retire as CEO on 1 January. Ian Clark performed his role as the CEO of Genentech for the last 15 years, bringing through 15 new drugs in the process and dealing with the after-effects of Roche’s buyout of the company.
Bill Anderson takes the positon of CEO after having worked within Genentech for the last decade. He has held a number of positions within the company and will switch to the role from his current position as North American commercial chief, a position he has held since July. Prior to this, he held the position of global product strategy chief for Roche and headed Genentech’s bio-oncology business.
“Bill is an outstanding leader with a deep understanding of the company and proven expertise in bringing important medicines to people with serious diseases,” said Daniel O’Day, CEO of Roche’s pharmaceuticals division.
Genentech has announced that it has entered into a multi-year strategic research collaboration with NVIDIA …
Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) …